Phaseline

Companies › Kadence Bio

Kadence Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KH-001 besylate–Phase 2Premature EjaculationNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07434271KH-001 besylatePhase 2Premature EjaculationPsychiatryNov 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Draig Therapeutics HB BioTech Beckley Psytech Synendos Therapeutics Neuroventi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.